These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35262277)

  • 21. Amyloid fibril composition and transthyretin gene structure in senile systemic amyloidosis.
    Gustavsson A; Jahr H; Tobiassen R; Jacobson DR; Sletten K; Westermark P
    Lab Invest; 1995 Nov; 73(5):703-8. PubMed ID: 7474944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.
    Sousa MM; Fernandes R; Palha JA; Taboada A; Vieira P; Saraiva MJ
    Am J Pathol; 2002 Nov; 161(5):1935-48. PubMed ID: 12414539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Age-related oxidative modifications of transthyretin modulate its amyloidogenicity.
    Zhao L; Buxbaum JN; Reixach N
    Biochemistry; 2013 Mar; 52(11):1913-26. PubMed ID: 23414091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clusterin regulates transthyretin amyloidosis.
    Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
    Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.
    Cardoso I; Saraiva MJ
    FASEB J; 2006 Feb; 20(2):234-9. PubMed ID: 16449795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.
    Sousa MM; Cardoso I; Fernandes R; Guimarães A; Saraiva MJ
    Am J Pathol; 2001 Dec; 159(6):1993-2000. PubMed ID: 11733349
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of cardiac transthyretin amyloidosis: an update.
    Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
    Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wild type transthyretin cardiac amiloidozis as a rare and overlooked underlying etiology in a patient with heart failure with preserved ejection fraction and left ventricular hypertrophy.
    Murat S; Çavuşoğlu Y; Ak Sivrikoz İ
    Turk Kardiyol Dern Ars; 2021 Oct; 49(7):579-584. PubMed ID: 34623301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology.
    Bergström J; Gustavsson A; Hellman U; Sletten K; Murphy CL; Weiss DT; Solomon A; Olofsson BO; Westermark P
    J Pathol; 2005 Jun; 206(2):224-32. PubMed ID: 15810051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular mechanisms of metabolic syndrome-related atrial decompensation in a rat model of HFpEF.
    Hohendanner F; Bode D; Primessnig U; Guthof T; Doerr R; Jeuthe S; Reimers S; Zhang K; Bach D; Wakula P; Pieske BM; Heinzel FR
    J Mol Cell Cardiol; 2018 Feb; 115():10-19. PubMed ID: 29289652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.
    Manral P; Reixach N
    Biosci Rep; 2015 Jan; 35(1):. PubMed ID: 25395306
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
    Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
    Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum transthyretin monomer in patients with familial amyloid polyneuropathy.
    Sekijima Y; Tokuda T; Kametani F; Tanaka K; Maruyama K; Ikeda S
    Amyloid; 2001 Dec; 8(4):257-62. PubMed ID: 11791618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
    João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
    J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Amyloidogenic Transthyretin Drives Hepatic Proteostasis Remodeling in an Induced Pluripotent Stem Cell Model of Systemic Amyloid Disease.
    Giadone RM; Liberti DC; Matte TM; Rosarda JD; Torres-Arancivia C; Ghosh S; Diedrich JK; Pankow S; Skvir N; Jean JC; Yates JR; Wilson AA; Connors LH; Kotton DN; Wiseman RL; Murphy GJ
    Stem Cell Reports; 2020 Aug; 15(2):515-528. PubMed ID: 32735824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detailed structural analysis of amyloidogenic wild-type transthyretin using a novel purification strategy and mass spectrometry.
    Kingsbury JS; Théberge R; Karbassi JA; Lim A; Costello CE; Connors LH
    Anal Chem; 2007 Mar; 79(5):1990-8. PubMed ID: 17261023
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trapping the monomer of a non-amyloidogenic variant of transthyretin: exploring its possible use as a therapeutic strategy against transthyretin amyloidogenic diseases.
    Palhano FL; Leme LP; Busnardo RG; Foguel D
    J Biol Chem; 2009 Jan; 284(3):1443-53. PubMed ID: 18984591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.